Royalty Pharma Plc (RPRX)
Healthcare
Biotechnology
58.40 $
-1.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Royalty Pharma Plc (RPRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 19,621 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47 | 10,816 | 10,482 | 11,374 | 11,370 | 12,450 | 21,097 | 17,516 | 16,813 | 16,382 | 18,223 | 19,621 | |
| 47 | 3,044 | 3,004 | 2,948 | 2,609 | 832 | 2,697 | 2,878 | 2,555 | 1,274 | 1,802 | 619 | |
| 47 | 1,721 | 1,674 | 1,382 | 1,924 | 246 | 1,009 | 1,541 | 1,711 | 477 | 929 | 619 | |
| – | 1,721 | 1,674 | 1,382 | 2,386 | 793 | 1,992 | 2,803 | 2,428 | 1,234 | 1,771 | 637 | |
| – | – | – | – | 199 | 39 | 39 | 68 | 37 | 22 | 27 | 884 | |
| – | – | – | – | 19 | – | 657 | 0.0 | 0.0 | – | – | – | |
| 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | 0.0 | 925 | |
| – | 6,949 | – | – | 76 | 52 | 29 | 5.7 | 15 | 1.8 | 15,127 | – | |
| 2.9 | 6,119 | 6,022 | 6,904 | 6,818 | 6,308 | 6,124 | 7,267 | 7,288 | 6,298 | 7,880 | 9,906 | |
| 2.9 | 314 | 297 | 383 | 580 | 333 | 308 | 171 | 1,167 | 161 | 1,254 | 636 | |
| – | 184 | 173 | 281 | 281 | 282 | 282 | 6,892 | 998 | – | 998 | 380 | |
| 2.1 | 2.0 | 1.9 | – | 4.5 | 11 | 11 | 5.6 | 7.9 | 15 | 13 | 19 | |
| – | – | – | – | 6,238 | 5,956 | 5,817 | 7,096 | 6,119 | 6,135 | 6,615 | 8,571 | |
| 44 | 4,677 | 4,446 | 4,461 | 4,488 | 6,106 | 14,973 | 10,249 | 5,628 | 6,526 | 6,947 | 6,477 | |
| -273 | -302 | -320 | – | 1,216 | 2,825 | 1,921 | 2,255 | 1,965 | 2,518 | 2,846 | 2,356 | |
| 354 | 607 | 607 | 354 | 354 | 354 | 375 | 415 | 565 | 603 | 594 | 560 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.